Fecal Biomarkers in the Diagnosis and Monitoring of Crohn's Disease

被引：35
作者：
Wright, Emily K. [1 ,2 ]
De Cruz, Peter [1 ,2 ]
Gearry, Richard [3 ,4 ]
Day, Andrew S. [3 ,4 ]
Kamm, Michael A. [1 ,2 ]
机构：
[1] St Vincents Hosp, Melbourne, Vic 3065, Australia
[2] Univ Melbourne, Melbourne, Vic, Australia
[3] Christchurch Hosp, Christchurch, New Zealand
[4] Univ Otago, Christchurch, New Zealand
来源：
INFLAMMATORY BOWEL DISEASES | 2014年 / 20卷 / 09期
关键词：
Crohn's disease; inflammatory bowel disease; stool tests; fecal biomarkers; calprotectin; lactoferrin; S100A12; postoperative; INFLAMMATORY-BOWEL-DISEASE; C-REACTIVE PROTEIN; INTESTINAL INFLAMMATION; CALPROTECTIN LEVELS; ULCERATIVE-COLITIS; NONINVASIVE MARKER; SURROGATE MARKERS; COLORECTAL-CANCER; ACTIVITY INDEX; GASTROINTESTINAL SYMPTOMS;
D O I：
10.1097/MIB.0000000000000087
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
The diagnosis and monitoring of Crohn's disease has traditionally relied on clinical assessment, serum markers of inflammation, and endoscopic examination. Fecal biomarkers such as calprotectin, lactoferrin, and S100A12 are predominantly derived from neutrophils, are easily detectable in the feces, and are emerging as valuable markers of intestinal inflammation. This review focuses on the role of fecal biomarkers in the diagnosis and monitoring of Crohn's disease, in particular how these biomarkers change with disease activity and remission, how they can be used to monitor the response to medical therapy, their value in predicting clinical relapse, and their role in monitoring the postoperative state.
引用
收藏
页码：1668 / 1677
页数：10
相关论文
共 110 条
[41]   Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levels [J].
Hamalainen, Anssi ;
Sipponen, Taina ;
Kolho, Kaija-Leena .
WORLD JOURNAL OF GASTROENTEROLOGY, 2011, 17 (47) :5166-5171
[42]   The Diagnostic Accuracy of Fecal Calprotectin During the Investigation of Suspected Pediatric Inflammatory Bowel Disease [J].
Henderson, Paul ;
Casey, Aoife ;
Lawrence, Sally J. ;
Kennedy, Nicholas A. ;
Kingstone, Kathleen ;
Rogers, Pam ;
Gillett, Peter M. ;
Wilson, David C. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 (06) :941-949
[43]   Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT) [J].
Hoff, G ;
Grotmol, T ;
Thiis-Evensen, E ;
Bretthauer, M ;
Gondal, G ;
Vatn, MH .
GUT, 2004, 53 (09) :1329-1333
[44]  
Husebye E, 2001, AM J GASTROENTEROL, V96, P2683
[45]   DEVELOPMENT AND VALIDATION OF A PEDIATRIC CROHNS-DISEASE ACTIVITY INDEX [J].
HYAMS, JS ;
FERRY, GD ;
MANDEL, FS ;
GRYBOSKI, JD ;
KIBORT, PM ;
KIRSCHNER, BS ;
GRIFFITHS, AM ;
KATZ, AJ ;
GRAND, RJ ;
BOYLE, JT ;
MICHENER, WM ;
LEVY, JS ;
LESSER, ML .
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 1991, 12 (04) :439-447
[46]   Fecal calprotectin is equally sensitive in Crohn's disease affecting the small bowel and colon [J].
Jensen, Michael Dam ;
Kjeldsen, Jens ;
Nathan, Torben .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2011, 46 (06) :694-700
[47]  
JONES JR, 2008, CONSUM REP, V73, P6
[48]   Age-related faecal calprotectin, lactoferrin and tumour M2-PK concentrations in healthy volunteers [J].
Joshi, Shilpa ;
Lewis, Stephen J. ;
Creanor, Siobhan ;
Ayling, Ruth M. .
ANNALS OF CLINICAL BIOCHEMISTRY, 2010, 47 :259-263
[49]   Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome [J].
Kaiser, T. ;
Langhorst, J. ;
Wittkowski, H. ;
Becker, K. ;
Friedrich, A. W. ;
Rueffer, A. ;
Dobos, G. J. ;
Roth, J. ;
Foell, D. .
GUT, 2007, 56 (12) :1706-1713
[50]   Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study [J].
Kallel, Lamia ;
Ayadi, Imen ;
Matri, Samira ;
Fekih, Monia ;
Ben Mahmoud, Nadia ;
Feki, Moncef ;
Karoui, Sami ;
Zouari, Bechir ;
Boubaker, Jalel ;
Kaabachi, Naziha ;
Filali, Azza .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2010, 22 (03) :340-345
12345678910